Kriya Medical Technologies Receives License From CDSCO For RSV, Covid Testing Kit
Kriya Medical Technologies, a Chennai-based medical devices company, has received its manufacturing license from the Central Drugs Standard Control Organization (CDSCO) for its product KRIVIDA Trivus Respi Panel RT-qPCR Kit, the company informed in a press statement.
The kit has the unique capability to simultaneously identify Respiratory Syncytial Virus (RSV), Influenza viruses and SARS-CoV-2 in patients presenting with respiratory tract infections, the company said.
KRIVIDA Trivus Respi Panel RT-qPCR kit has been validated by ICMR at the National Institute of Virology, Pune, and the kit has shown 100 per cent specificity and 99.11 per cent sensitivity for the detection of all three viruses.
A key feature of this kit is its ability to detect RSV, a virus that primarily causes viral pneumonia in children under the age of 5 and contributes significantly to hospitalisations. Additionally, RSV is a common cause of lower respiratory tract diseases (LRTD) in older adults, potentially leading to life-threatening pneumonia and bronchiolitis, the company's statement read.
In India, influenza accounts for 35 per cent of all respiratory tract infections. In severe cases, the progression from influenza-like illness (ILI) to acute lung injury and acute respiratory distress syndrome can be rapid, resulting in high mortality rates. The Krivida Trivus Respi Panel RT-qPCR Kit helps in the early detection of influenza, thereby enabling the prompt initiation of specific antiviral medications.
Dr Shanmugapriya, MD, R&D Head, Kriya Medical Technologies said “12.9 per cent of infant deaths in India is caused by pneumonia. 29 per cent of infants with pneumonia are infected with Respiratory Syncytial Virus in India. The mortality rate of RSV infection in a healthy infant is 0.5 to 1.7 per cent and is as high as 60 per cent in immunocompromised infants."
Dr Shanmugapriya further said that the rationale behind the design of the Krivida Trivus Multiplex RT PCR kit is grounded in the recognition of the fact that timely and accurate diagnosis of RSV is key for avoiding severe forms of pneumonia and death, and this helps in a significant reduction in the infant mortality rate.
"We decided to include Influenza detection, as Influenza (A and B) causes 29 per cent of pneumonia in infants and using a specific antiviral drug in the earliest phase of illness can reduce the burden of complications," Dr Shanmugapriya added.
The company further stated that the kit can also detect co-infections, which are associated with increased disease severity, morbidity, and mortality due to a weakened immune system. The Krivida Trivus Respi Panel RT-qPCR Kit is a valuable tool for improving diagnostic and infection control capacity.
Anu Moturi, CEO and Founder, of Kriya Medical Technologies, said, “In the wake of the upcoming Flu season, the Krivida Trivus Respi Panel RT-qPCR Kit is timely and essential since it helps with accurate and rapid identification of the responsible pathogens, enabling healthcare providers to initiate appropriate treatments promptly, reducing the risk of complications and improving patient outcomes."
